Advertisement

Topics

Matinas BioPharma Holdings, Inc. Company Profile

23:24 EDT 19th March 2019 | BioPortfolio

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its LNC platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.


News Articles [1520 Associated News Articles listed on BioPortfolio]

Matinas BioPharma CEO says company is beating out competitor for reducing serum triglycerides

Matinas BioPharma Holdings Inc (NYSE:MTNB) CEO Jerry Jabbour speaks to Proactive's Christine Corrado at the MicroCap Conference in New York. Matinas BioPharma is a clinical-stage biopharmaceutical...

Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001

Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic ...

Matinas BioPharma to Present at the MicroCap Conference

BEDMINSTER, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delive...

Matinas BioPharma to Present at Biotech Showcase 2019

– Presentation with live audio webcast Monday, January 7th at 3:30 PM PST – BEDMINSTER, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinica...

Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer

BEDMINSTER, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed Keith A. Ku...

Matinas BioPharma to Present at the 8th Annual Partnership Opportunities in Drug Delivery Conference

BEDMINSTER, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that Raphael Mannino, Ph.D., Chie...

Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update

–  Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3...

Matinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

BEDMINSTER, N.J., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delive...

PubMed Articles [10 Associated PubMed Articles listed on BioPortfolio]

Biopharma dealmaking in 2018.

Destroyed by Slavery? Slavery and African American Family Formation Following Emancipation.

This study introduces a new sample that links people and families across 1860, 1880, and 1900 census data to explore the intergenerational impact of slavery on black families in the United States. Sla...

Six-Year Prospective Outcomes of Primary Breast Augmentation With Nano Surface Implants.

Motiva Implants (Establishment Labs Holdings Inc.) are a novel family of silicone breast implants using cutting-edge technologies engineered to optimize aesthetic and safety outcomes.

Early clinical results with the Tendyne transcatheter mitral valve replacement system.

Transcatheter mitral valve replacement is an emerging technology for the treatment of mitral valve regurgitation. Numerous devices are in development and in various stages of clinical investigation. T...

Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation.

At the turn of the century, the pharmaceutical industry began a transition toward a focus on oncology, rare diseases, and other areas of high unmet need that required a new, more complex approach to d...

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease

To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the prod...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1

This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann-Pick disease Type C1 (NPC-1) is safe at 3 different dose l...

Companies [622 Associated Companies listed on BioPortfolio]

Matinas BioPharma Holdings, Inc.

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and me...

Cornerstone BioPharma Holdings, Inc.

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Kedrion Biopharma, Inc.

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and pre...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

More Information about "Matinas BioPharma Holdings, Inc." on BioPortfolio

We have published hundreds of Matinas BioPharma Holdings, Inc. news stories on BioPortfolio along with dozens of Matinas BioPharma Holdings, Inc. Clinical Trials and PubMed Articles about Matinas BioPharma Holdings, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Matinas BioPharma Holdings, Inc. Companies in our database. You can also find out about relevant Matinas BioPharma Holdings, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record